Demonstration of Multi-Season Efficacy and Immunogenicity of CodaVax Intranasal Influenza Vaccine
Farmingdale, New York, January 6, 2017 – Codagenix, Inc., a clinical stage, venture and public sector-funded small business, announced today data demonstrating multi-season efficacy for its intranasal Influenza A vaccine. Multiple studies conducted in pigs and ferrets have shown that the Codagenix H1N1 live-attenuated influenza vaccine, CodaVax-H1N1, induces a robust immune response to multiple seasonal strains of influenza and protects against challenge using seasonally drifted strains. Using their proprietary, synthetic biology-based vaccine design platform, Codagenix has generated an intranasal, live-attenuated Influenza vaccine that works at ultralow doses – a dose that is 4-6 orders of magnitude lower than the current Flu Shot.
“Current commercial influenza vaccines still use an egg-grown, inactivated-virus that requires a high dose of antigen,” commented Dr. Steffen Mueller, Chief Scientific Officer. “Using an inactivated virus requires continual updates to the vaccine each season and as we know, this can leads to vaccines that aren’t matched to the circulating virus or have very low efficacy against the circulating virus. Our goal is to make a vaccine that won’t require updating each year, but rather one that can provide multi-season protection with improved efficacy.”
There is currently no vaccine on the market that can protect people from the flu for multiple years. In the released data set, Codagenix demonstrates that CodaVax-H1N1 induces a robust immune response against both the 2016 and 2017 influenza strains, demonstrating the multi-season potential of their vaccine..
“We are excited to demonstrate the potential of our ultra-low dose influenza vaccine and its ability to provide multi-season protection,” COO J. Robert Coleman said, “Our ‘disruptive’ genome recoding technology seeks to shake up the vaccine industry’s status quo, providing a rational means to designing vaccines. The flu vaccine industry is in need of a next-generation product that can provide improved efficacy across multiple seasons, and we believe CodaVax-H1N1 is well positioned to disrupt the market and reduce the disease burden of influenza.”
Codagenix has already manufactured clinical trial material of their intranasal influenza vaccine CodaVax-H1N1, with recruitment and dosing for a Phase I/II clinical trial scheduled for Q1-2017
Figure. Pigs and ferrets were vaccinated a single time intranasally using CodaVax-H1N1 at an ultra-low dose. Antibodies to H1N1 CA/7/09 and H1N1 MI/45/15 were measured in serum 28-35 days post vaccination.
Codagenix Inc., a biotechnology company on Long Island, New York, is developing live attenuated vaccines using a “disruptive” software-based rational design algorithm that is unlike previous vaccine “platforms”. By leveraging the redundancy in the genetic code (various codons exist at the gene level to encode the same amino acid at the protein level), the Codagenix algorithm re-structures viral genomes into a sub-optimal genetic code. The so-called “deoptimized” viruses have resulted in highly attenuated vaccine strains that are effective at greatly reduced doses, because they present every antigen of the pathogen, while being 100% identical to the target pathogen at the protein level. The Codagenix pipeline of vaccines includes Influenza, respiratory syncytial virus (RSV), Dengue, foot-and-mouth disease virus (FMDV), pathogenic E. coli, and other pathogens.
J. Robert Coleman, PhD, MBA
Chief Operating Officer